Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patientsAnna S. Berghoff, Peter Birner, Christoph Zielinski et al.|The Breast|2014Cited by 69
Prognostic impact of breast cancer subtypes in elderly patientsElisabeth Bergen, Rupert Bartsch, Cornelia Tichy et al.|Breast Cancer Research and Treatment|2016Cited by 25
Coexpression of HER3 as a predictor of survival in HER2-positve breast cancer patients.Rupert Bartsch, Christoph Zielinski, Anna S. Berghoff et al.|Journal of Clinical Oncology|2013Cited by 3
Abstract P1-09-10: Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancerCF Singer, YY Tan, Florian Fitzal et al.|Cancer Research|2017Cited by 2
Abstract P2-08-17: Prognostic impact of breast cancer subtypes in elderly patientsES Bergen, Rupert Bartsch, Cornelia Tichy et al.|Cancer Research|2016Cited by 1